Related Experiment Video
Updated: Feb 19, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
734
[Myelosupression induced by linezolid: a pediatric case]
María Del M Ballesteros García1, María E Orós Milián2, Elena Díaz Velázquez2
1Servicio de Pediatría, Hospital Universitario de Fuenlabrada, Madrid, España. mballesterosgarcia@gmail.com.
Archivos Argentinos De Pediatria
|November 1, 2017
Summary
Linezolid antibiotic treatment can cause myelosuppression, affecting blood cell production. Monitoring blood counts is crucial during prolonged linezolid therapy to manage potential toxicity.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Linezolid is a key antibiotic for treating Gram-positive resistant infections.
- Oxazolidinone class antibiotics inhibit protein synthesis.
- Common side effects include gastrointestinal issues, neuropathy, and myelosuppression.
Observation:
- A 12-year-old boy with hip septic osteoarthritis and femoral osteomyelitis received linezolid.
- The patient experienced digestive intolerance and weight loss.
- Blood tests revealed severe anemia, leukopenia, and thrombocytopenia, indicating hematopoiesis disorder.
Findings:
- Hematological abnormalities suggested linezolid-induced drug toxicity.
- These adverse effects resolved upon discontinuation of linezolid.
- Myelosuppression is typically associated with linezolid treatment exceeding 28 days.
Implications:
- This case highlights the potential for reversible myelosuppression with linezolid.
- Regular blood count monitoring is essential for patients on extended linezolid therapy.
- Early detection and intervention can mitigate linezolid-related hematological toxicity.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
289
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
258
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
258
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
338
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
338
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
344
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
344
01:29Drug Dosing: Infants and Children
344
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
344